Amit Sonawane, 35, an engineer at the district health office, gets his first vaccine dose in Palghar, India. Viraj Nayar for NPR hide caption
Amit Sonawane, 35, an engineer at the district health office, gets his first vaccine dose in Palghar, India.
Viraj Nayar for NPRThe world has a new coronavirus mutant spreading from one continent to another — and it looks like a tough one to stop.
The World Health Organization declared on Monday that the variant in India, known as B.1.617, is officially a "variant of concern."
"There is some available information to suggest increased transmissibility of B.1.617," the WHO's Marie Van Kerkhove said Monday from Geneva. Last week, NPR published a story explaining why B.1.617 could be the fastest spreading mutant on the planet.
At the same time, researchers around the globe have been rushing to figure out if the COVID-19 vaccines available will still be effective against this new mutant. Some preliminary data, published on Sunday and Monday, offer a glimmer of hope.
Like other variants of concern, B.1.617 has more than a dozen mutations. But two mutations in particular have been most concerning, says Ravindra Gupta, a microbiologist at Cambridge University. These mutations are found on an important part of the virus — where the immune system attacks.
"So that's why this variant was labeled 'a double mutant,' " Gupta says. "It had these two big mutations, in two big places and that's what caused all the worries."
Each of these mutations — or similar versions of them — have cropped up separately in other parts of the world, including one in California and one in Brazil. Previous studies have shown that these mutations, individually, give the virus an advantage against the immune system. It reduces the ability of antibodies to fight off the virus.
So what happens when the two mutations come together? The concern, Gupta says, is that the effect of the mutations would add up or even amplify each other. In other words, could the "double mutant" be "double trouble" for the vaccine?
"So we set up quickly to try and figure out whether this was a real concern," he says.
The Palghar Rural Hospital has chairs lined up — at a safe distance — for vaccine patients. But so far there are more chairs than vaccine candidates. Viraj Nayar for NPR hide caption
Gupta and his team took antibodies from people vaccinated with the Pfizer shot and then looked to see how much the two mutations, when combined together, decreased the ability of these antibodies to kill the virus. What they saw was hopeful. The double mutant behaved a lot like the single mutant. It wasn't double trouble.
"There didn't seem to be the addition of one mutant on top of the other," Gupta says. "And that was really quite important because that assumption has caused panic."
The team published their findings online on Sunday. At the same time, researchers at Emory University performed similar studies with antibodies taken from 15 people who have been vaccinated with either the Pfizer or the Moderna shots. In these studies, the antibodies could still neutralize the B.1.617 variant, but the potency of the antibodies dropped by about 7-fold on average, the authors report.
"Despite this reduction, all vaccine blood samples ... still maintained the ability to block the Indian variant," says immunologist Mehul Suthar at Emory University, who led the study.
Together the data suggest the Pfizer and Moderna vaccines will still work well against B.1.617, just as they do for the variant from South Africa, known as B.1.351. In both cases, the shots will likely offer high protection from death and severe illness, but they may lose some ability to stop mild or asymptomatic infections.
"These findings highlight the need to increase vaccination rates," Suthar says.
That's great news for people in the U.S., where these vaccines are available. But in India, the most common vaccine is the one developed by AstraZeneca and manufactured by the Serum Institute, called Covishield. How will this vaccine fare against B.1.617?
Preliminary evidence suggests this vaccine will also be able to prevent severe cases and deaths, says Rakesh Mishra, advisor to the Centre for Cellular & Molecular Biology in Hyderabad, India.
He and his colleagues have been running experiments similar to the ones Suthar and his colleagues have performed, except with Covishield. The team hasn't published their results yet, but Mishra says the results look similar to what other researchers have found with the Pfizer and Moderna vaccines.
"We were actually very relieved," Mishra says, "because this means this variant has not managed to resist the vaccines."
And the world has — once again — gotten lucky, he says; the best tools to fight COVID-19, not only still work, but they are still powerful.
The Link LonkMay 13, 2021 at 01:22AM
https://ift.tt/3bkmUO2
Will Vaccines Work On India's Coronavirus Variant? : Goats and Soda - NPR
https://ift.tt/2VuKK1x
Work
No comments:
Post a Comment